Want to see FDMT full AI Analyst Report?
4D Molecular Therapeutics (FDMT) AI Stock Analysis
4D Molecular Therapeutics
(NASDAQ:FDMT)
The score is primarily held back by weak financial performance—large ongoing losses and heavy cash burn—despite a low-leverage balance sheet and improving revenue. Technical indicators also point to continued negative momentum. Valuation is difficult to assess due to negative earnings, while the recent Phase 3 start and supportive clinical data provide a meaningful (but risk-dependent) positive offset.
4D Molecular Therapeutics (FDMT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $628.13M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.01M
- Price to Earnings (P/E)
- -4.2
- Beta (1Y)
- 0.73
- Revenue Growth
- 278712.12%
- EPS Growth
- 26.59%
- Country
- US
- Employees
- 196
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
4D Molecular Therapeutics Business Overview & Revenue Model
Company Description
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a tri...
4D Molecular Therapeutics Financial Statement Overview
Summary
Revenue has stepped up sharply (TTM $92.0M), but the company remains far from profitable with a large TTM net loss (-$179.2M), deeply negative net margin (~-195%), and materially negative EBIT/EBITDA. Cash flow is a key weakness (TTM operating cash flow -$156.1M; free cash flow -$156.7M), increasing funding needs. The balance sheet is a relative strength with low debt ($19.6M; debt-to-equity ~0.05), though equity has declined, reflecting ongoing burn.
Income Statement
32NegativeBalance Sheet
70PositiveCash Flow
40Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.01M | 85.21M | 37.00K | 20.72M | 3.13M | 18.04M |
| Gross Profit | 38.65M | 77.58M | -141.26M | -76.37M | -77.12M | -43.32M |
| EBITDA | -183.96M | -132.48M | -154.16M | -95.09M | -103.61M | -68.30M |
| Net Income | -179.18M | -140.11M | -160.87M | -100.84M | -107.49M | -71.32M |
Balance Sheet | ||||||
| Total Assets | 492.62M | 566.71M | 560.38M | 339.89M | 261.85M | 353.49M |
| Cash, Cash Equivalents and Short-Term Investments | 361.33M | 402.65M | 424.88M | 288.23M | 213.55M | 247.78M |
| Total Debt | 39.22M | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M |
| Total Liabilities | 84.96M | 61.05M | 49.78M | 32.06M | 30.51M | 34.38M |
| Stockholders Equity | 407.66M | 505.66M | 510.61M | 307.83M | 231.34M | 319.11M |
Cash Flow | ||||||
| Free Cash Flow | -156.67M | -109.08M | -138.37M | -78.56M | -98.22M | -78.24M |
| Operating Cash Flow | -156.07M | -109.08M | -134.59M | -75.79M | -86.69M | -69.13M |
| Investing Cash Flow | -16.64M | -92.97M | -302.44M | 115.72M | -17.05M | -172.68M |
| Financing Cash Flow | 165.92M | 112.96M | 337.25M | 156.83M | 3.08M | 118.09M |
4D Molecular Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Negative. The current price of 11.44 is below the 20-day moving average (MA) of 12.32, below the 50-day MA of 13.63, and above the 200-day MA of 10.89, indicating a neutral trend. The MACD of -0.47 indicates Negative momentum. The RSI at 41.05 is Neutral, neither overbought nor oversold. The STOCH value of 49.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FDMT.
4D Molecular Therapeutics Risk Analysis
4D Molecular Therapeutics disclosed 87 risk factors in its most recent earnings report. 4D Molecular Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New Risks4D Molecular Therapeutics Peers Comparison
Overall Rating
ASMB62Neutral
AURA54Neutral
KRRO53.6Neutral
DSGN52Neutral- FDMT50Neutral
IMRX47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ASMB | 62Neutral | $409.86M | 35.47 | -0.02% | ― | 125.12% | 98.69% |
| AURA | 54Neutral | $636.75M | -3.39 | -73.18% | ― | ― | 9.05% |
| KRRO | 54Neutral | $210.80M | -1.58 | -114.26% | ― | -62.08% | -2.62% |
| DSGN | 52Neutral | $668.37M | -8.60 | -34.03% | ― | ― | -5.51% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FDMT | 50Neutral | $657.41M | -4.18 | -41.33% | ― | 278712.12% | 26.59% |
| IMRX | 47Neutral | $242.54M | -3.39 | -33.91% | ― | ― | 42.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics, Inc. | 11.37 | 0.62 | 5.77% | |
| ASMB | Assembly Biosciences Inc | 19.51 | -11.92 | -37.93% | |
| KRRO | Korro Bio, Inc. | 15.85 | -18.01 | -53.19% | |
| DSGN | Design Therapeutics, Inc. | 10.15 | 3.91 | 62.66% | |
| IMRX | Immuneering Corp. Class A | 3.49 | -2.89 | -45.30% | |
| AURA | Aura Biosciences Inc | 6.03 | 0.35 | 6.16% |
4D Molecular Therapeutics Corporate Events
4D Molecular Therapeutics Begins Phase 3 4D-150 DME Trial
PositiveOn September 28, 2026, 4D Molecular Therapeutics reported that it has enrolled the first patients across multiple global sites in 4SIGHT, a Phase 3 randomized, double-masked trial of intravitreal gene therapy 4D-150 versus aflibercept in treatment-na...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026